We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MDRNA, Inc. Acquires Bridged Nucleic Acid (BNA) Patents to Broaden Its RNAi-Drug Discovery Platform
News

MDRNA, Inc. Acquires Bridged Nucleic Acid (BNA) Patents to Broaden Its RNAi-Drug Discovery Platform

MDRNA, Inc. Acquires Bridged Nucleic Acid (BNA) Patents to Broaden Its RNAi-Drug Discovery Platform
News

MDRNA, Inc. Acquires Bridged Nucleic Acid (BNA) Patents to Broaden Its RNAi-Drug Discovery Platform

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MDRNA, Inc. Acquires Bridged Nucleic Acid (BNA) Patents to Broaden Its RNAi-Drug Discovery Platform"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MDRNA, Inc, a leading RNAi-based drug discovery and development company, announced today that it has acquired intellectual property for bridged nucleic acids from Valeant Pharmaceuticals North America. Bridged nucleic acids (BNA) are novel nucleoside analogs in which the flexible ribose sugar is locked into a rigid conformation by a small chemical linker. When included in single or double stranded oligonucleotides, the highly stable A-form of RNA or DNA is favored, resulting in increased thermal stability of a duplex or higher affinity of a single strand for its complementary target, e.g., messenger RNA. In addition BNAs provide resistance to nuclease degradation.

"The BNA technology provides MDRNA a unique position in the development of RNA therapeutics," stated Barry Polisky, Chief Scientific Officer of MDRNA. "BNA is highly complementary to our proprietary unlocked nucleobase analog (UNA) technology and enables MDRNA to tailor key characteristics of our UsiRNA constructs to impart greater versatility and specificity. Additionally, BNA strengthens MDRNA's proprietary meroduplex constructs and are directly applicable to alternative oligonucleotide constructs including single strand molecules and constructs which function outside of an RNAi mechanism."

The patent estate offers MDRNA considerable breadth in the research and development of nucleic acid-based therapies to include not only those with an RNAi mechanism of action, such as siRNA and miRNA, but those that function to inhibit RNA by a diverse set of mechanisms.

"We are focused on becoming the preeminent RNAi-based therapeutics company," stated J. Michael French, President and CEO of MDRNA. "The addition of this key intellectual property places us in a position to provide a broader array of RNAi-based drug discovery technologies to potential pharmaceutical partners and allows us entry into an important emerging therapeutic space driven by single stranded RNA constructs."

With the addition the of the BNA patent estate, MDRNA owns or controls 15 issued or allowed patents, and has 37 pending patent applications, 126 pending foreign patent applications and 7 PCT applications.

Advertisement